Contrast enhancement is a prognostic factor in IDH1/2 mutant, but not in wild-type WHO grade II/III glioma as confirmed by machine learning.
Sign Up to like & getrecommendations! Published in 2019 at "European journal of cancer"
DOI: 10.1016/j.ejca.2018.10.019
Abstract: BACKGROUND Mutation of the isocitrate dehydrogenase (IDH) gene and co-deletion on chromosome 1p/19q is becoming increasingly relevant for the evaluation of clinical outcome in glioma. Among the imaging parameters, contrast enhancement (CE) in WHO II/III… read more here.
Keywords: iii; glioma; contrast enhancement; grade iii ... See more keywords
P14.59 Post-Market Surveillance Data of the EMEA region indicate good tolerability of TTFields in WHO Grade III Glioma
Sign Up to like & getrecommendations! Published in 2019 at "Neuro-Oncology"
DOI: 10.1093/neuonc/noz126.294
Abstract: Despite considerable progress in molecular characterization and evidence for certain regimens, treatment of grade III gliomas is still ambiguous and, with surgery, radiotherapy and chemotherapy, in analogy to grade IV glioma treatment. Tumor treating fields… read more here.
Keywords: emea region; glioma; surveillance; grade iii ... See more keywords
Importance of evaluating health-related quality of life issues in survivors of WHO grade II or III gliomas
Sign Up to like & getrecommendations! Published in 2022 at "Neuro-Oncology Practice"
DOI: 10.1093/nop/npab067
Abstract: Gliomas account for 80% of all malignant primary brain and CNS tumors in adults.1 About 45% of these glial tumors are composed of several different histologies, including grade II and III astrocytoma and oligodendroglioma. Patients… read more here.
Keywords: iii glioma; grade iii; hrqol issues; treatment ... See more keywords